Related Experiment Video
Updated: Mar 7, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Double Sequential Encrypted Targeting Sequence: A New Concept for Bone Cancer Treatment
Gonzalo Villaverde1, Valentina Nairi1, Alejandro Baeza1
1Depto. Química Inorgánica y Bioinorgánica, Facultad de Farmacia, Universidad Complutense de Madrid. Plaza Ramon y CajaLs/n. Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12 ¡ Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
Abstract:
The selective transportation of therapeutic agents to tumoral cells is usually achieved by their conjugation with targeting moieties able to recognize these cells. Unfortunately, simple and static targeting systems usually show a lack in selectivity. Herein, a double sequential encrypted targeting system is proposed as a stimuli-responsive targeting analogue for selectivity enhancement. The system is able to recognize diseased bone tissue in the first place, and once there, a hidden secondary targeting group is activated by the presence of an enzyme overproduced in the malignant tissue (cathepsin K), thereby triggering the recognition of diseased cells. Transporting the cell targeting agent in a hidden conformation that contains a high selective tissular primary targeting, could avoid not only its binding to similar cell receptors but also the apparition of the binding-site barrier effect, which can enhance the penetration of the therapeutic agent within the affected zone. This strategy could be applied not only to conjugate drugs but also to drug-loaded nanocarriers to improve the efficiency for bone cancer treatments.
Insights
A novel double sequential encrypted targeting system enhances drug delivery selectivity to bone cancer cells. This stimuli-responsive system uses a primary targeting of diseased tissue and a secondary enzyme-activated targeting for improved therapeutic agent delivery.
Area of Science:
- Biomedical Engineering
- Drug Delivery Systems
- Oncology
Background:
- Selective drug delivery to tumor cells is crucial for effective cancer treatment.
- Current targeting moieties often lack sufficient selectivity, leading to off-target effects.
- The binding-site barrier effect can impede therapeutic agent penetration into tumor sites.
Purpose of the Study:
- To develop a stimuli-responsive, double sequential encrypted targeting system for enhanced selectivity in bone cancer treatment.
- To improve the penetration and efficacy of therapeutic agents by overcoming limitations of static targeting systems.
Main Methods:
- Design of a dual-targeting system with an initial tissue-specific recognition.
- Incorporation of a secondary, enzyme-activated targeting group (cathepsin K) for malignant cell recognition.
- Conformation change strategy to mask and then reveal the targeting agent.
Main Results:
- The proposed system demonstrates sequential targeting: initial recognition of diseased bone tissue.
- Activation of the secondary targeting group by overexpressed cathepsin K in malignant tissue.
- Potential to avoid non-specific binding and the binding-site barrier effect for improved drug penetration.
Conclusions:
- The double sequential encrypted targeting system offers enhanced selectivity for bone cancer therapy.
- This strategy can be applied to both conjugated drugs and drug-loaded nanocarriers.
- Improved targeting efficiency holds promise for advancing bone cancer treatment outcomes.
